These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16412857)

  • 1. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
    Bleske BE; Nicklas JM; Bard RL; Brook RD; Gurbel PA; Bliden KP; Rajagopalan S; Pitt B
    J Am Coll Cardiol; 2006 Jan; 47(2):338-41. PubMed ID: 16412857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia.
    Rosenson RS; Wolff D; Tangney CC
    Clin Sci (Lond); 2004 Feb; 106(2):215-7. PubMed ID: 12967321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of statins in patients with non-ischemic heart failure.
    Laufs U; Wassmann S; Schackmann S; Heeschen C; Böhm M; Nickenig G
    Z Kardiol; 2004 Feb; 93(2):103-8. PubMed ID: 14963675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
    Nawawi H; Osman NS; Yusoff K; Khalid BA
    Horm Metab Res; 2003 Aug; 35(8):479-85. PubMed ID: 12953165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
    Michelena HI; Osorio LA; Citkowitz E
    Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
    Mozaffarian D; Minami E; Letterer RA; Lawler RL; McDonald GB; Levy WC
    Am J Cardiol; 2005 Dec; 96(12):1699-704. PubMed ID: 16360360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity.
    Antoniades C; Bakogiannis C; Tousoulis D; Reilly S; Zhang MH; Paschalis A; Antonopoulos AS; Demosthenous M; Miliou A; Psarros C; Marinou K; Sfyras N; Economopoulos G; Casadei B; Channon KM; Stefanadis C
    Circulation; 2010 Sep; 122(11 Suppl):S66-73. PubMed ID: 20837928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy.
    Bielecka-Dabrowa A; Goch JH; Mikhailidis DP; Rysz J; Maciejewski M; Banach M
    Med Sci Monit; 2009 Dec; 15(12):MS12-23. PubMed ID: 19946241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
    Dogra GK; Watts GF; Chan DC; Stanton K
    Diabet Med; 2005 Mar; 22(3):239-42. PubMed ID: 15717868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD; Kleit AN; Nietert PJ; Ornstein S
    Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.